Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. Mulls Registration Fees For Foreign Drug Manufacturers

This article was originally published in PharmAsia News

Executive Summary

In light of recent safety concerns about foreign-manufactured pharmaceutical products, members of the U.S. Congress are considering whether to introduce registration fees for foreign drug manufacturers exporting products to the U.S

You may also be interested in...



Contaminant Discovered In Chinese-Produced Heparin API

U.S FDA has discovered "significant quantities" of a heparin-like contaminant in tested samples of heparin API manufactured by Baxter-supplier Scientific Protein Laboratories' Changzhou plant

Heparin Investigation Highlights Foreign Inspection Gap – Former FDA Officials

Members of Congress have jumped on the reported admission by U.S. FDA that it did not inspect a Changzhou City, China plant that provides active pharmaceutical ingredients for Baxter Healthcare's injectable heparin as a symbol of FDA's inability to adequately inspect pharmaceuticals manufactured abroad

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel